Unity Biotechnology, Inc.
NASDAQ: UBX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anirvan Ghosh
- Employees
- 16
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $3.4M
- Website
- https://unitybiotechnology.com
Loading UBX…
Loading profile data…Frequently asked questions about UBX
What does Unity Biotechnology, Inc. (UBX) do?
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema,...
Where does UBX trade?
Unity Biotechnology, Inc. (UBX) trades on the NASDAQ Global Select.
What sector is UBX in?
Unity Biotechnology, Inc. (UBX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Unity Biotechnology, Inc.?
Anirvan Ghosh is the chief executive officer of Unity Biotechnology, Inc. (UBX).
Where is Unity Biotechnology, Inc. headquartered?
Unity Biotechnology, Inc. is headquartered in United States.
Does UBX pay a dividend?
Unity Biotechnology, Inc. (UBX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did UBX go public?
Unity Biotechnology, Inc. (UBX) completed its initial public offering in 2018.